海翔药业(002099) - 2021 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2021 was CNY 642,309,773.93, an increase of 11.63% compared to CNY 575,373,970.84 in the same period last year[9] - Net profit attributable to shareholders was CNY 57,187,894.76, a decrease of 45.60% from CNY 105,120,332.86 year-on-year[9] - Net profit excluding non-recurring gains and losses was CNY 55,546,159.19, down 44.75% from CNY 100,536,464.90 in the previous year[9] - Basic earnings per share were CNY 0.04, down 33.33% from CNY 0.06 in the same period last year[9] - Net profit for the period was CNY 56,846,105.31, down 45.8% from CNY 105,120,332.86 in the same period last year[73] Cash Flow - Net cash flow from operating activities was CNY 123,247,740.86, a decline of 34.52% compared to CNY 188,208,215.04 last year[9] - Net cash flow from operating activities decreased by 34.52% to ¥123,247,740.86, attributed to a reduction in cash received from sales[24] - The cash flow from operating activities is ¥123,247,740.86, a decrease from ¥188,208,215.04 in the previous period[89] - The net cash flow from financing activities was $196,155,513.88, a significant improvement compared to the previous period's negative cash flow of -$458,667,291.91[91] - The net cash flow from operating activities was $222,978,106.43, a recovery from a negative cash flow of -$157,880,869.80 in the prior period[92] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,517,274,005.66, an increase of 4.72% from CNY 7,178,568,316.07 at the end of the previous year[9] - Total liabilities increased to CNY 1,551,863,888.36 from CNY 1,326,499,002.45, which is an increase of approximately 17.0%[57] - The company's total assets reached CNY 5,918,560,277.28, up from CNY 5,677,871,495.63, showing growth in the company's asset base[67] - Total liabilities increased to CNY 1,017,612,166.48 from CNY 818,850,421.49, indicating a rise in financial obligations[67] - Total current liabilities were CNY 1,181,753,985.96, with significant components including short-term borrowings of CNY 360,380,416.67 and accounts payable of CNY 24,740,003.62[106] Shareholder Information - The company had a total of 36,514 common shareholders at the end of the reporting period[14] - The largest shareholder, Zhejiang Donggang Investment Co., Ltd., held 34.22% of the shares[14] - Net assets attributable to shareholders were CNY 5,965,768,160.24, up 1.94% from CNY 5,852,085,567.11 at the end of last year[9] - The company's equity attributable to shareholders reached CNY 5,852,085,567.11, remaining stable compared to the previous period[101] Research and Development - R&D expenses increased by 55.58% to ¥40,190,992.54 primarily due to the amortization of the employee stock ownership plan[24] - Research and development expenses increased to CNY 40,190,992.54, compared to CNY 25,833,575.74, indicating a focus on innovation[70] - Research and development expenses for the current period are ¥9,754,224.34, an increase from ¥5,715,238.88 in the previous period[78] Investment and Financing Activities - Investment cash flow net amount was -¥117,383,069.08, a 372.47% increase in outflow due to increased fixed asset purchases[24] - The company raised a total of RMB 1,026,869,436.44 through a non-public offering of 99,890,023 shares at RMB 10.28 per share, with net proceeds after fees amounting to RMB 1,014,403,606.71[40] - The company reported a financial expense of -¥6,920,403.39, compared to -¥5,042,516.21 in the previous period[78] Compliance and Governance - The company has committed to avoiding competition with its subsidiaries and ensuring fair pricing in related party transactions[34] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[45][46] - The company strictly adheres to its commitments regarding non-competition and related party transactions[34] Miscellaneous - The company has resumed production at Zhenggang Dyeing after receiving approval from the local environmental authority[27] - The company has not engaged in any securities or derivative investments during the reporting period[38][39] - The first quarter report for 2021 was not audited, indicating preliminary financial results[110]